Actorius Launches Integrated Liquid Biopsy Tests at CAMO 2026 Symposium
At the CAMO 2026 symposium in Navi Mumbai, Actorius Innovations and Research introduced its integrated liquid biopsy portfolio, including next-generation sequencing (NGS) genomic tests and the CDSCO-approved OncoDiscover circulating tumor cell (CTC) biomarker platform. These technologies enable precise cancer treatment decisions and monitoring of minimal residual disease by analyzing ctDNA, gDNA, RNA, and rare circulating tumor cells. Developed under Dr. Jayant Khandare, OncoDiscover is India's first clinical assay for CTC detection across over fifteen solid tumor types. Experts praised the combined approach for enhancing accessible liquid biopsy in India.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (77/100). Lens Score 43/100.
Outlets measured: thetribune, businessstandard, thetribune. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–78/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thetribune broke this story on 27 Oct, 10:37 am. Other outlets followed.